An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis

Kurt Jaeckle, Tracy Batchelor, Steven J. O'Day, Surasak Phuphanich, Pamela New, Glenn Lesser, Allen Cohn, Mark Gilbert, Robert Aiken, Deborah Heros, Lisa Rogers, Eric Wong, Dorcas Fulton, John C. Gutheil, Said Baidas, Julia M. Kennedy, Warren Mason, Paul Moots, Christy Russell, Lode J. Swinnen & 1 others Stephen B. Howell

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Drugs currently available for intrathecal administration are cleared rapidly from the CSF. DepoCyt is a slow-release formulation of cytarabine that maintains cytotoxic concentrations of free cytarabine in the CSF for > 14 days following a single injection. DepoCyt was administered to 110 patients with a diagnosis of neoplastic meningitis based on either a positive CSF cytology (76) or neurologic and CT or MRI scan findings sufficient to document neoplastic meningitis (34). Patients were treated with DepoCyt 50 mg every 2 weeks for 1 month of induction therapy by either lumbar puncture (LP) or intraventricular (IVT) injection. Patients without neurologic progression were candidates to receive an additional 3 months of consolidation therapy. All patients received dexamethasone 4 mg BID on days 1-5 of each cycle. Median time to neurologic progression was 55 days; median overall survival was 95 days. Among the 76 patients with a positive CSF cytology at baseline, 70 were evaluable for response, and of this group19 (27%) attained the criteria for response (cytologic response in the absence of neurologic progression). The most important adverse events were headache and arachnoiditis. When drug-related, these were largely low grade, transient, and reversible. Drug-related grade 3 headache occurred on 4% of cycles; grade 3 or 4 arachnoiditis occurred on 6% of cycles. No cumulative toxicity was observed. DepoCyt injected once every 2 weeks produced a response-rate comparable to that previously reported for methotrexate given twice a week. The once in every 2-week-dosing interval offers an advantage over conventional schedules (2-3 doses/week) used for other agents available for intrathecal injection.

Original languageEnglish (US)
Article number405930
Pages (from-to)231-239
Number of pages9
JournalJournal of Neuro-Oncology
Volume57
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Cytarabine
Meningitis
Nervous System
Arachnoiditis
Neoplasms
Headache
Cell Biology
Pharmaceutical Preparations
Intraventricular Injections
Therapeutics
Spinal Injections
Spinal Puncture
Methotrexate
Dexamethasone
Appointments and Schedules
Magnetic Resonance Imaging
Injections
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Jaeckle, K., Batchelor, T., O'Day, S. J., Phuphanich, S., New, P., Lesser, G., ... Howell, S. B. (2002). An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis. Journal of Neuro-Oncology, 57(3), 231-239. [405930]. https://doi.org/10.1023/A:1015752331041
Jaeckle, Kurt ; Batchelor, Tracy ; O'Day, Steven J. ; Phuphanich, Surasak ; New, Pamela ; Lesser, Glenn ; Cohn, Allen ; Gilbert, Mark ; Aiken, Robert ; Heros, Deborah ; Rogers, Lisa ; Wong, Eric ; Fulton, Dorcas ; Gutheil, John C. ; Baidas, Said ; Kennedy, Julia M. ; Mason, Warren ; Moots, Paul ; Russell, Christy ; Swinnen, Lode J. ; Howell, Stephen B. / An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis. In: Journal of Neuro-Oncology. 2002 ; Vol. 57, No. 3. pp. 231-239.
@article{58b904b4fea64fd29fa1b69e2084e54d,
title = "An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis",
abstract = "Drugs currently available for intrathecal administration are cleared rapidly from the CSF. DepoCyt is a slow-release formulation of cytarabine that maintains cytotoxic concentrations of free cytarabine in the CSF for > 14 days following a single injection. DepoCyt was administered to 110 patients with a diagnosis of neoplastic meningitis based on either a positive CSF cytology (76) or neurologic and CT or MRI scan findings sufficient to document neoplastic meningitis (34). Patients were treated with DepoCyt 50 mg every 2 weeks for 1 month of induction therapy by either lumbar puncture (LP) or intraventricular (IVT) injection. Patients without neurologic progression were candidates to receive an additional 3 months of consolidation therapy. All patients received dexamethasone 4 mg BID on days 1-5 of each cycle. Median time to neurologic progression was 55 days; median overall survival was 95 days. Among the 76 patients with a positive CSF cytology at baseline, 70 were evaluable for response, and of this group19 (27{\%}) attained the criteria for response (cytologic response in the absence of neurologic progression). The most important adverse events were headache and arachnoiditis. When drug-related, these were largely low grade, transient, and reversible. Drug-related grade 3 headache occurred on 4{\%} of cycles; grade 3 or 4 arachnoiditis occurred on 6{\%} of cycles. No cumulative toxicity was observed. DepoCyt injected once every 2 weeks produced a response-rate comparable to that previously reported for methotrexate given twice a week. The once in every 2-week-dosing interval offers an advantage over conventional schedules (2-3 doses/week) used for other agents available for intrathecal injection.",
author = "Kurt Jaeckle and Tracy Batchelor and O'Day, {Steven J.} and Surasak Phuphanich and Pamela New and Glenn Lesser and Allen Cohn and Mark Gilbert and Robert Aiken and Deborah Heros and Lisa Rogers and Eric Wong and Dorcas Fulton and Gutheil, {John C.} and Said Baidas and Kennedy, {Julia M.} and Warren Mason and Paul Moots and Christy Russell and Swinnen, {Lode J.} and Howell, {Stephen B.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1023/A:1015752331041",
language = "English (US)",
volume = "57",
pages = "231--239",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Jaeckle, K, Batchelor, T, O'Day, SJ, Phuphanich, S, New, P, Lesser, G, Cohn, A, Gilbert, M, Aiken, R, Heros, D, Rogers, L, Wong, E, Fulton, D, Gutheil, JC, Baidas, S, Kennedy, JM, Mason, W, Moots, P, Russell, C, Swinnen, LJ & Howell, SB 2002, 'An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis', Journal of Neuro-Oncology, vol. 57, no. 3, 405930, pp. 231-239. https://doi.org/10.1023/A:1015752331041

An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis. / Jaeckle, Kurt; Batchelor, Tracy; O'Day, Steven J.; Phuphanich, Surasak; New, Pamela; Lesser, Glenn; Cohn, Allen; Gilbert, Mark; Aiken, Robert; Heros, Deborah; Rogers, Lisa; Wong, Eric; Fulton, Dorcas; Gutheil, John C.; Baidas, Said; Kennedy, Julia M.; Mason, Warren; Moots, Paul; Russell, Christy; Swinnen, Lode J.; Howell, Stephen B.

In: Journal of Neuro-Oncology, Vol. 57, No. 3, 405930, 01.01.2002, p. 231-239.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An open label trial of sustained-release cytarabine (DepoCyt蒂) for the intrathecal treatment of solid tumor neoplastic meningitis

AU - Jaeckle, Kurt

AU - Batchelor, Tracy

AU - O'Day, Steven J.

AU - Phuphanich, Surasak

AU - New, Pamela

AU - Lesser, Glenn

AU - Cohn, Allen

AU - Gilbert, Mark

AU - Aiken, Robert

AU - Heros, Deborah

AU - Rogers, Lisa

AU - Wong, Eric

AU - Fulton, Dorcas

AU - Gutheil, John C.

AU - Baidas, Said

AU - Kennedy, Julia M.

AU - Mason, Warren

AU - Moots, Paul

AU - Russell, Christy

AU - Swinnen, Lode J.

AU - Howell, Stephen B.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Drugs currently available for intrathecal administration are cleared rapidly from the CSF. DepoCyt is a slow-release formulation of cytarabine that maintains cytotoxic concentrations of free cytarabine in the CSF for > 14 days following a single injection. DepoCyt was administered to 110 patients with a diagnosis of neoplastic meningitis based on either a positive CSF cytology (76) or neurologic and CT or MRI scan findings sufficient to document neoplastic meningitis (34). Patients were treated with DepoCyt 50 mg every 2 weeks for 1 month of induction therapy by either lumbar puncture (LP) or intraventricular (IVT) injection. Patients without neurologic progression were candidates to receive an additional 3 months of consolidation therapy. All patients received dexamethasone 4 mg BID on days 1-5 of each cycle. Median time to neurologic progression was 55 days; median overall survival was 95 days. Among the 76 patients with a positive CSF cytology at baseline, 70 were evaluable for response, and of this group19 (27%) attained the criteria for response (cytologic response in the absence of neurologic progression). The most important adverse events were headache and arachnoiditis. When drug-related, these were largely low grade, transient, and reversible. Drug-related grade 3 headache occurred on 4% of cycles; grade 3 or 4 arachnoiditis occurred on 6% of cycles. No cumulative toxicity was observed. DepoCyt injected once every 2 weeks produced a response-rate comparable to that previously reported for methotrexate given twice a week. The once in every 2-week-dosing interval offers an advantage over conventional schedules (2-3 doses/week) used for other agents available for intrathecal injection.

AB - Drugs currently available for intrathecal administration are cleared rapidly from the CSF. DepoCyt is a slow-release formulation of cytarabine that maintains cytotoxic concentrations of free cytarabine in the CSF for > 14 days following a single injection. DepoCyt was administered to 110 patients with a diagnosis of neoplastic meningitis based on either a positive CSF cytology (76) or neurologic and CT or MRI scan findings sufficient to document neoplastic meningitis (34). Patients were treated with DepoCyt 50 mg every 2 weeks for 1 month of induction therapy by either lumbar puncture (LP) or intraventricular (IVT) injection. Patients without neurologic progression were candidates to receive an additional 3 months of consolidation therapy. All patients received dexamethasone 4 mg BID on days 1-5 of each cycle. Median time to neurologic progression was 55 days; median overall survival was 95 days. Among the 76 patients with a positive CSF cytology at baseline, 70 were evaluable for response, and of this group19 (27%) attained the criteria for response (cytologic response in the absence of neurologic progression). The most important adverse events were headache and arachnoiditis. When drug-related, these were largely low grade, transient, and reversible. Drug-related grade 3 headache occurred on 4% of cycles; grade 3 or 4 arachnoiditis occurred on 6% of cycles. No cumulative toxicity was observed. DepoCyt injected once every 2 weeks produced a response-rate comparable to that previously reported for methotrexate given twice a week. The once in every 2-week-dosing interval offers an advantage over conventional schedules (2-3 doses/week) used for other agents available for intrathecal injection.

UR - http://www.scopus.com/inward/record.url?scp=0035990086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035990086&partnerID=8YFLogxK

U2 - 10.1023/A:1015752331041

DO - 10.1023/A:1015752331041

M3 - Article

VL - 57

SP - 231

EP - 239

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

M1 - 405930

ER -